Safety, effectiveness and treatment patterns of sodium zirconium cyclosilicate for hyperkalemia management in China: actualize study
Nan Shen, Xin Zeng, Hua Xie, L J Zhang, Jing Yang, Yongqiang Lin, Xinyu Liu, Xudong Cai 等 36 位
First Affiliated Hospital of Dalian Medical University Dalian Medical University Hebei Medical University First Affiliated Hospital of Hebei Medical University
阅读操作
确认中在文库中上传 PDF 后可生成中文音频讲解。
摘要与影响
Introduction This real-world analysis aimed to evaluate the primary endpoint safety profile and the secondary effectiveness and treatment patterns of sodium zirconium cyclosilicate (SZC) for hyperkalemia management in China, addressing the current evidence gap on SZC use in clinical practice. Methods This multi-center, prospective, non-interventional cohort study enrolled patients (aged ≥18 years), including new and ongoing SZC users, from 34-sites. Treatment was categorized into correction-phase (FAS-P1) and maintenance phase (FAS-P2, new and ongoing users). The subgroup analysis was performed in patients undergoing hemodialysis (full analysis set-hemodialysis [FAS-H]). The primary objective included the safety of SZC whereas treatment patterns and effectiveness were the secondary objectives. Results Of the 1,000 enrolled patients, 442, 878, and 474 were included in FAS-P1, FAS-P2, and FAS-H subgroups, respectively. The most frequently used SZC dosage was 5 g once-daily in FAS-P (42.1%), and FAS-P2 (37.7%). In the FAS-P1 and FAS-P2 groups, 64% and 65.4% of patients reported AEs; 26.9% and 30.8% reported SAEs. The serum potassium (sK + ) was reduced from 5.8 to 5.0 mmol/L in FAS-P1. The mean “with-in” sK + levels over 6-month was 5.1 mmol/L in FAS-P2, of which the new-user group were slightly higher vs. ongoing group of FAS-P2 with a mean sK + of 5.2 and 5.0 mmol/L, respectively. Furthermore, SZC showed good efficacy in patients with different chronic kidney disease stage subgroups of FAS-P2. Conclusion In real-world clinical practice, no new safety issues of SZC were identified. SZC was effective in lowering sK + levels in the correction-phase and remained stable during the maintenance-phase.
逐年被引趋势
关键指标
同类平均 = 1
同领域 · 同年份 · 同类型
Google Scholar 与 OpenAlex 的被引统计范围不同,数值存在差异属正常。
AI 辅助阅读
依据:摘要
可就本文提问;依据不足时会说明。
学术脉络
学科主题
生物医学Potassium and Related Disorders
Parathyroid Disorders and Treatments · Dialysis and Renal Disease Management